Published in Immunol Allergy Clin North Am on May 01, 2006
Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol (2009) 3.91
Circulating CD23+ B cell subset correlates with the development of resistance to Schistosoma mansoni reinfection in occupationally exposed adults who have undergone multiple treatments. J Infect Dis (2009) 1.11
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol (2015) 0.90
Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. Cell Mol Immunol (2015) 0.88
New roles for mast cells in modulating allergic reactions and immunity against pathogens. Curr Opin Immunol (2009) 0.83
An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. Mol Genet Metab (2011) 0.80
Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions. Curr Allergy Asthma Rep (2016) 0.80
Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest (2009) 4.10
Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 2.40
Ethnic variations in UK asthma frequency, morbidity, and health-service use: a systematic review and meta-analysis. Lancet (2005) 2.07
Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol (2003) 2.01
Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 1.94
Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.87
Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol (2007) 1.85
Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin Immunol (2006) 1.68
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy (2009) 1.65
Tregs and allergic disease. J Clin Invest (2004) 1.64
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol (2011) 1.62
Mechanisms of immunotherapy. J Allergy Clin Immunol (2004) 1.45
Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol (2008) 1.43
Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol (2008) 1.38
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33
Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol (2005) 1.30
Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol (2007) 1.28
Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol (2010) 1.27
Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol (2004) 1.26
Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.26
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol (2007) 1.22
Regulatory T cells and allergic disease. Inflamm Allergy Drug Targets (2008) 1.15
The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol (2003) 1.13
Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol (2007) 1.12
Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol (2005) 1.12
Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A? Proc Am Thorac Soc (2004) 1.09
Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol (2012) 1.08
Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol (2012) 1.08
Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol (2007) 1.06
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy (2012) 1.04
Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods (2012) 1.04
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03
Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03
Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol (2011) 1.02
Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J Immunol (2003) 1.02
IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol (2005) 1.01
Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology (2002) 1.00
Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol (2003) 0.99
CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol (2002) 0.99
Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol (2004) 0.98
Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol (2007) 0.96
IL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol (2012) 0.96
Germinal-centre reactions in allergic inflammation. Trends Immunol (2006) 0.95
Allergen immunotherapy and tolerance. Allergol Int (2013) 0.92
NHS allergy services in the UK: proposals to improve allergy care. Clin Med (2002) 0.91
One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol (2011) 0.90
Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther (2013) 0.90
Biased use of VH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis. J Allergy Clin Immunol (2005) 0.89
Serum immunologic markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am (2011) 0.88
Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol (2004) 0.87
Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. Am J Respir Crit Care Med (2002) 0.86
Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res (2006) 0.85
The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol (2010) 0.84
Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax (2013) 0.83
CXCR1+CD4+ T cells in human allergic disease. J Immunol (2004) 0.83
Postnasal drip and chronic cough: An open interventional study. Respir Med (2009) 0.82
Tobacco industry lobbyists and their health-care clients. Lancet (2013) 0.82
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol (2012) 0.82
Immunological responses to allergen immunotherapy. Clin Allergy Immunol (2004) 0.81
Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol (2012) 0.81
Mechanisms of sublingual immunotherapy. Immunol Allergy Clin North Am (2011) 0.81
Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol (2013) 0.80
Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother (2012) 0.79
Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep (2002) 0.78
Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). Clin Transl Allergy (2013) 0.77
Rhinitis with negative skin tests and absent serum allergen-specific IgE: more evidence for local IgE? J Allergy Clin Immunol (2009) 0.77
Immunomodulatory treatment strategies for allergic diseases. Curr Drug Targets Inflamm Allergy (2003) 0.76
Sublingual immunotherapy for allergic Rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol (2008) 0.76
Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med (2006) 0.75
Perennial rhinitis. BMJ (2007) 0.75
Treatment of seasonal allergic rhinitis: desensitisation for hay fever works. BMJ (2003) 0.75
Biomarkers of tolerance in response to allergen immunotherapy. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess (2013) 0.75
Tradition and innovation: finding the right balance. J Allergy Clin Immunol (2007) 0.75
Immunologic responses to subcutaneous allergen immunotherapy. Clin Allergy Immunol (2008) 0.75
Silk contact anaphylaxis. Contact Dermatitis (2014) 0.75
Allergen injection immunotherapy. Clin Allergy Immunol (2002) 0.75